Ipratropium Bromide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Ipratropium Bromide. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Upper respiratory tract infection | 34% |
| Bronchitis | 23% |
| Copd exacerbation | 23% |
| Sinusitis | 14% |
| Urinary tract infection | 10% |
| Headache | 9% |
| Influenza-like symptoms | 8% |
| Dyspnea | 8% |
| Back pain | 7% |
| Coughing | 6% |
| Rhinitis | 6% |
| Dyspepsia | 5% |
| Mouth dry | 4% |
| Nausea | 4% |
| Dizziness | 3% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Source: FDA labeling via NIH DailyMed (set b37e86c4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.